about
A Licensed Combined Haemophilus influenzae Type b-Serogroups C and Y Meningococcal Conjugate Vaccine.Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, AustraliaAntibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.Immunization During Pregnancy: Impact on the Infant.Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.Vaccine decision-making begins in pregnancy: Correlation between vaccine concerns, intentions and maternal vaccination with subsequent childhood vaccine uptake.Birth outcomes for Australian mother-infant pairs who received an influenza vaccine during pregnancy, 2012-2014: The FluMum study.Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine.Long-term persistence of immunity and B-cell memory following Haemophilus influenzae type B conjugate vaccination in early childhood and response to booster.B cell memory to a serogroup C meningococcal conjugate vaccine in childhood and response to booster: little association with serum IgG antibody.Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study.Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013.Time to Open Our Eyes? A Challenge to the Role of Polysomnography for Trials in Pediatric Sleep-Disordered Breathing.Patterns of tree nut sensitization and allergy in the first 6 years of life in a population-based cohortThe clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-b152. Protective Antibody Levels 7.5 Years After Primary Vaccination in Adolescence With a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults: Phase IIIb Clinical FindingAssociation of Rotavirus Vaccination With the Incidence of Type 1 Diabetes in ChildrenInfluenza and pertussis vaccination of women during pregnancy in Victoria, 2015–2017Persistence of pneumococcal antibodies after primary immunisation with a polysaccharide-protein conjugate vaccineImmunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.Recurrent apnoea post immunisation: Informing re-immunisation policyAntibody persistence in Australian adolescents following meningococcal C conjugate vaccinationPotential immediate hypersensitivity reactions following immunization in preschool aged children in Victoria, AustraliaImmunizations under sedation at a paediatric hospital in Melbourne, Australia from 2012-2016Providing opportunistic immunisations for at-risk inpatients in a tertiary paediatric hospitalPrevalence and natural history of tree nut allergyEmollients for prevention of atopic dermatitis in infancyMass cytometry reveals cellular fingerprint associated with IgE+ peanut tolerance and allergy in early lifeCASE SERIES: YELLOW FEVER VACCINATION IN EGG-ALLERGIC CHILDRENThe Effect of Maternal Immunisation During Pregnancy on Infant Vaccine ResponsesDoes rotavirus turn on type 1 diabetes?Biological sex influences antibody responses to routine vaccinations in the first year of lifeDiagnosing Peanut Allergy with Fewer Oral Food ChallengesVaccine Allergy? Skin Testing and Challenge at a Tertiary Pediatric Hospital in Melbourne, AustraliaAntibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccineRecurrence risk of a hypotonic hyporesponsive episode in two Australian specialist immunisation clinicsImpact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial
P50
Q33939014-60C90510-9C36-41B5-9E98-CF7A1429BF1BQ35886931-A79ED0B6-20DF-4489-997D-8F7C2A41DEB9Q38373610-910BC4EF-341F-4AF2-BAB2-D381736A5348Q38392949-7D8BE485-161A-4BAD-81BD-80AAE5196447Q38683189-D645956C-E442-4584-92BF-1D202075329FQ39350694-769608B8-3493-4B75-AD3B-1DB98377CF09Q40082181-998F6474-C634-4EE2-A738-C91DDDE86906Q40335426-2B21B3F4-5660-40F9-83D6-E28B81B775FAQ41077558-32C111D2-C1AF-4F4B-9F2C-B07CDDEA8DDAQ45340766-D515D300-6265-48AB-8354-A22CD1FDD276Q50735672-B020399C-5BD9-4E1C-950F-E6441E7B5123Q50922862-45CED429-1B68-45E4-B66C-8F095F6140AFQ51824053-6B702811-D62D-4678-8FEE-C7F5E09F588EQ52675105-5A35E925-70CE-4EC5-BD08-A37B9433C2EAQ53603140-35F6E0EF-9611-4FC5-9C50-4ECE0761805AQ55359739-0B245915-3221-4635-BC32-A7B6207FD8CFQ57166710-185D1A76-494D-4BB8-A25C-9855D7E9BD70Q58811316-C8395049-A8A5-4D4A-869F-17CC14C38352Q59328667-61C984B3-37C0-477A-B46E-334803AF4EAAQ61387141-72FF456A-2899-40EB-A907-871B14DEA9E5Q63814972-07387628-D9F6-4DAC-8D38-FFFC2999BD10Q64129238-2223D59E-100A-4850-8AE2-68258B34CAF0Q64949643-2C30503C-23E2-4265-825E-1FA330FF1F8BQ84409556-F4B836BC-DAE5-4583-867C-417A6EFD63B3Q86872420-F59525EB-9AFE-4AD2-890E-784775B1B14EQ88291256-6F7637DC-5A0F-46CF-B3C3-2DED8A04B26CQ88649463-4C0F4517-9C35-4BBD-AEFD-71C669459D56Q89501678-82759762-E1F7-46B5-AF89-D46D651BE1EBQ89651522-B72EFB2F-AF07-4196-A682-EE4F7D31E16EQ89840784-5E9B41B2-19FD-4D0F-8D4B-2917777F9807Q89926597-54E3FD27-F743-4828-BBDD-9F4889C5CDEAQ89970382-67E19B49-4CF0-4DDE-B1FB-01E7C08CFC0BQ90090202-50BC431B-B24E-4F55-9E89-121EFF82EBF2Q90629848-2E598E5A-2842-4C5A-B32C-607963E46003Q90697921-B4DB967C-D5E5-4E40-9CFE-0CF661BD9BD8Q90727511-DEE69D7A-0C50-44DB-8E70-710D2D51448FQ91224338-296A50C1-59B1-4CB5-A510-0EB8FA437CD7Q91257609-75B0DC55-5AA6-441C-9246-65E04F4580B2Q91346423-5966B26B-9D9A-4C5E-8D24-D939C15D20EAQ91494915-D96611C6-C3A6-4CEE-9BDE-BB9EB894DCE1
P50
description
researcher ORCID ID = 0000-0002-5683-996X
@en
wetenschapper
@nl
name
Kirsten Perrett
@ast
Kirsten Perrett
@en
Kirsten Perrett
@es
Kirsten Perrett
@nl
type
label
Kirsten Perrett
@ast
Kirsten Perrett
@en
Kirsten Perrett
@es
Kirsten Perrett
@nl
prefLabel
Kirsten Perrett
@ast
Kirsten Perrett
@en
Kirsten Perrett
@es
Kirsten Perrett
@nl
P31
P496
0000-0002-5683-996X